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ABSTRACT  
Objective: The DEPDC5 (DEP domain-containing protein 5) gene, encoding a repressor of the 
mTORC1 signaling pathway, has recently emerged as a major gene mutated in familial focal 
epilepsies. We aimed to further extend the role of DEPDC5 to focal cortical dysplasias (FCDs). 
Methods: Seven patients from four families with DEPDC5 mutations, and focal epilepsy 
associated with FCD were recruited and investigated at the clinical, neuroimaging and 
histopathological levels. The DEPDC5 gene was sequenced from genomic blood and brain 
DNA. 
Results: All patients had drug-resistant focal epilepsy, five of them underwent surgery, and 
one a brain biopsy. Electroclinical phenotypes were compatible with FCD II, although MRI 
was typical in only four cases. Histopathology confirmed FCD IIa in two patients (including 
one MRI-negative case) and showed FCD I in two other patients, and remained inconclusive 
in the last two. Three patients were seizure-free post-surgically and one had a worthwhile 
improvement. Sequencing of blood DNA revealed truncating DEPDC5 mutations in all four 
families; one mutation was found to be mosaic in an asymptomatic father. A brain somatic 
DEPDC5 mutation was identified in one patient in addition to the germline mutation.  
Interpretation: Germline, germline mosaic and brain somatic DEPDC5 mutations may cause 
epilepsy associated with FCD, reinforcing the link between mTORC1 pathway and FCDs. 
Similarly to other mTORopathies, a “two-hit” mutational model could be responsible for 
cortical lesions. Our study also indicates that epilepsy surgery is a valuable alternative in the 
treatment of drug-resistant DEPDC5-positive focal epilepsies, even if the MRI is 
unremarkable. 
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INTRODUCTION 
Focal epilepsies are the most frequent epilepsies. It is increasingly recognized that focal 
epilepsies are likely to have a genetic basis. During the last two decades, a number of 
mutations have been identified in autosomal dominant focal epilepsies, in both ion-channel 
(CHRNA4, CHRNB2, CHRNA2, KCNT1) and non-ion channel genes (LGI1, DEPDC5). 1, 2 Focal 
cortical dysplasias (FCDs), in particular FCD II, are well-known underlying neuropathological 
conditions for severe therapy-refractory epilepsies. 3, 4 Typically, FCDs II are characterized by 
a focal epilepsy of early onset, a drug-resistance, sleep-related seizures usually of 
extratemporal (often frontal) origin, and stereoelectroencephalography (SEEG) often showing 
subcontinuous repetitive spikes and spikes and waves alternating with bursts of fast activity. 
5-7 In the 2011 consensus classification of the International League Against Epilepsy (ILAE), 
FCD I referred to architectural disturbances of cortical lamination. Dysmorphic neurons are 
the histopathologic hallmark of FCD IIa and association with balloon cells specifies FCD IIb. 8 
FCD II occurs mainly sporadically, but rare familial cases have been reported. 9 Several rare 
mutations in CNTNAP2 (contactin associated protein-like 2), PTEN (phosphatase and tensin 
homolog) and SCN1A (alpha 1 subunit, sodium voltage-gated channel) have been associated 
with FCDs. 10  
Mutations of the DEPDC5 (DEP domain containing protein 5) gene account for 12 to 37 % 
of inherited focal epilepsies, including familial focal epilepsy with variable foci (FFEVF), 
autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and familial temporal lobe 
epilepsy (FTLE). 11-13 Recently, DEPDC5 mutations were also identified in rare cases of 
rolandic epilepsy and unclassified focal childhood epilepsies 14, as well as in three patients (in 
two families) with bottom-of-the-sulcus dysplasia and one with focal band heterotopia. 15 
Recent studies have shown that DEPDC5 is an upstream negative regulator of mammalian 
target of rapamycin mTOR complex 1 (mTORC1) in both mammalian cells 16 and yeast. 17 The 
mTORC1 signaling pathway regulates many major cellular processes including cell 
proliferation, growth and survival, and protein synthesis. 18 Upregulation of the pathway is 
implicated in the pathogenesis of numerous neurological conditions associated with cortical 
malformations and intractable seizures including FCDs IIb 19, TSC (tuberous sclerosis complex) 
20, PMSE (polyhydramnios, megalencephaly and symptomatic epilepsy) syndrome 21 and HME 
(hemimegalencephaly). 22 Besides, a causal link between mTOR hyperactivation and 
epileptogenesis is well recognized. 23 Here, we confirm that mutations in mTORC1 repressor 
DEPDC5 cause drug-resistant focal epilepsy associated with FCDs. We describe the 
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electroclinical and imaging phenotypes in seven patients from four families who were 
referred for epilepsy surgery, and report histological data and surgical outcomes. 
SUBJECTS AND METHODS  
Patients 
Two French (families 1 and 2), one American (family 3) and one French-Canadian (family 4) 
families were recruited. Our criteria for inclusion in the cohort were: 1) the presence of at 
least two family members with focal epilepsy, 2) transmission compatible with autosomal 
dominant inheritance, 3) at least one family member with a diagnosis of FCD according to 
the electroclinical features with positive MRI, or negative MRI with histological confirmation, 
and 4) a pathogenic DEPDC5 mutation in the affected family members. Nocturnal frontal 
lobe epilepsy (NFLE) was defined by clusters of short-duration (less than one minute) 
hyperkinetic, tonic or dystonic seizures, occurring predominantly during sleep. Written 
informed consent was obtained from all participants (or the parents of minors). The study 
was approved by the local ethics committee (CCPPRB of Pitié-Salpêtrière Hospital, Paris, No. 
69-03, 25/9/2003). 
Histopathology  
Human tissue specimens removed for the treatment of medically intractable epilepsy were 
analyzed by histology in five patients obtained from Rennes University (patients 1/IV-9 and 
1/V-1), Saint-Anne Hospital in Paris (patient 2/II-2), Ann & Robert H. Lurie Children's Hospital 
of Chicago (patient 3/IV-2) and CHUM Notre-Dame in Montreal (patient 4/III-1). Brain 
specimens were fixed in 4% paraformaldehyde and embedded in paraffin. All fixed tissue 
blocks were sectioned at 8 μm. Histopathological examination of the cortical specimen was 
carried out on hematoxylin and eosin (HE) stained paraffin-embedded tissue. FCDs were 
classified according to the ILAE classification. 8  
Genetic study 
Genomic DNA from blood samples was extracted using standard procedures. Genomic DNA 
from brain paraffin-embedded sections was available from 2 patients (1/IV-9 and 2/II-2), and 
was isolated and purified using the iPrep ChargeSwitch® Forensic Kit (Invitrogen™). All 42 
coding exons and intron-exon junctions of DEPDC5 (except exon 2 which was analyzed by 
Sanger sequencing) were analyzed by universal tailed amplicon sequencing as previously 
described. 12 DEPDC5 cDNA refers to NCBI reference sequence # NM_001242896.1 and 
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DEPDC5 protein to reference protein # NP_001229825.1. Ultra-deep sequencing (> 1000 X) 
to search for mosaic mutations in family 2 was performed on MiSeq (Illumina). Paternity test 
was performed using the AmpFLSTR® Profiler Plus® (Life technologies) in family 2. 
RESULTS  
Clinical and neuroimaging data (see Table 1, Figure 1) 
Family 1, diagnosed with FFEVF, was previously reported (referred to as family S) 12, 24 and 
was further investigated in this study. Patient 1/IV-9 had drug-resistant MRI-negative NFLE. 
Intracranial recordings by SEEG demonstrated interictal, almost continuous, rhythmic spike 
activity co-localized with subclinical ictal discharges arising from the left lateral premotor 
cortex. Low frequency stimulation in the same area elicited three clinical seizures similar to 
the spontaneous ones. This electrophysiological pattern was highly suggestive of FCD II, as 
previously described. 5 A focal resection guided by the results of the SEEG completely 
suppressed the seizures (13-year follow-up). However, due to technical problems, 
histopathology failed to identify the typical pattern corresponding to FCD II and only revealed 
a mild cytoarchitectonic perturbation compatible with FCD I (data not shown). His son, 
individual 1/V-4, suffered from nocturnal seizures suggestive of NFLE. A ketogenic diet in 
association with vigabatrin and phenytoin was effective for only 10 months. MRI showed 
abnormalities typical of FCD IIb in the left frontal lobe (Fig 2A-D). He is currently under 
presurgical evaluation. A second-degree female cousin of individual 1/V-4, individual 1/V-1, 
suffered from NFLE associated with an abnormal left precentral gyrus compatible with FCD II. 
A limited surgical resection was performed after SEEG at the age of 13, followed by a mild 
hemiparesis without reducing seizure frequency. Histopathology revealed fragmented and 
ischemic surgical specimens, precluding a reliable analysis (data not shown). 
Family 2 consisted of two sisters with nocturnal focal seizures. Patient 2/II-2 had drug-
resistant epilepsy and underwent a presurgical assessment. MRI was negative, but FDG-PET 
showed focal hypometabolism in the anterior part of the left insula (Fig 2E). SEEG confirmed 
the concordance between the hypometabolic area and the typical FCD II EEG pattern, with a 
seizure onset zone in the insula and early spread to the frontal lobe. After a limited resection 
of the left anterior insula, a seizure-free period of six months was obtained, but seizure 
recurrence required a complementary stereotaxic thermocoagulation within the neighboring 
anterior insular region, with a favorable outcome (4-year follow-up). Histopathological 
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examination of a small fragment showed large dysmorphic neurons in favor of FCD IIa (Fig 
3A-C). Her sister, individual 2/II-1, suffered from focal seizures suggestive of NFLE, sensitive 
to carbamazepine, which was discontinued two years later without seizure recurrence. Brain 
MRI (3 T) was normal. 
Family 3 included individual 3/IV-2 who had his first seizures at two years of age. Seizures 
were first sensitive to carbamazepine but a drug-resistance appeared at the age of five years. 
Semiology was suggestive of NFLE, MRI was normal, and presurgical evaluation implicated a 
precentral location. Because of the functional risks, surgery was limited to a surface biopsy 
from the suspect area. Histology revealed FCD I but the macroscopic anatomy (small area of 
pale cortex, firm to touch), suggested it may have been surrounded by FCD II (data not 
shown). Seizure frequency remained unchanged. Several family members on the father’s side 
had a similar history of seizures (Fig 1), although all had spontaneous remission and did not 
participate in the study. 
Family 4 comprises a male and his nephew with high suspicion of FCD II in both. Individual 
4/II-1 suffered from nocturnal sensorimotor seizures related to a dysplastic lesion located in 
the central region. Despite four resections, the patient was not seizure-free, but a 
worthwhile improvement was obtained. The excessive fragmentation of the surgical 
specimens precluded a reliable histologic diagnosis (data not shown). Individual 4/III-1 
suffered from drug-resistant focal epilepsy from the age of four years (previously reported 
25). Electroclinical features, including MRI, SPECT, FDG-PET and magnetoencephalography 
localized the epileptogenic zone to the right anterior frontal lobe (Fig 2F). A right anterior 
frontal corticectomy led to seizure freedom off all antiepileptic drugs (seven-year follow-up). 
Histopathological examination revealed FCD IIa (Fig 3B-D). 
Germline DEPDC5 mutations 
We applied targeted high-coverage sequencing of DEPDC5 exons and intron-exon junctions in 
the probands of the four families followed by a validation with Sanger sequencing. Pedigrees 
and molecular findings are illustrated in Figure 1. 
DEPDC5 c.715C>T (p.Arg239*) mutation was previously reported to segregate among 
affected family members in family 1, including patients 1/IV-9 and 1/V-1 who underwent 
epilepsy surgery. 12 We showed that the DEPDC5 transcript carrying the p.Arg239* mutation 
is targeted by nonsense-mediated decay and leads to DEPDC5 haploinsufficiency. 12 A novel 
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mutation, c.484-1G>A, located in the acceptor splice site of intron 8 and predicted to induce 
exon 9 skipping, was identified in the proband (2/II-2) of family 2. The c.484-1G>A mutation 
was also present in the affected sister (2/II-1), but was undetectable by traditional Sanger 
sequencing in the parents, in whom paternity was confirmed. Deep-targeted sequencing of 
DEPDC5 exon 9 was subsequently performed in both parents, and allowed detection of the 
c.484-1G>A mutation in ~ 5% (56/1038 reads) of the alleles of the asymptomatic father (2/I-
2), indicating germline mosaicism. In families 3 and 4, two novel nonsense mutations, 
c.1264C>T (p.Arg422*) and c.1759C>T (p.Arg587*) respectively, were identified. All the 
above mutations were considered pathogenic since they either introduced a premature stop 
codon or affected an essential splice site. They are not reported in the dbSNP135, 1000 
Genomes Project database or the NHLBI exome variant server database.  
Somatic DEPDC5 mutations 
We searched for DEPDC5 somatic mutations in brain specimens from patients 1/IV-9 and 
2/II-2. DNA was extracted from paraffin-embedded tissue and DEPDC5 sequencing 
performed either by targeted or traditional Sanger sequencing when amplification of 
targeted regions failed (exons 2, 12, 18). Sequencing confirmed the presence of the germline 
mutations p.Arg239* in patient 1/IV-9 and c.484-1G>A in patient 2/II-2. In addition, we also 
detected a second nonsense mutation located in exon 18, c.1264C>T (p.Arg422*) in 
individual 1/IV-9 (yet not detected in blood DNA with deep sequencing > 300 X) by Sanger 
sequencing (Fig 4). PCR amplification and sequencing were repeated from two independent 
extractions of brain tissue. The quality of brain DNA isolated from formalin-fixed, paraffin-
embedded tissue precluded deep sequencing to evaluate the level of mosaicism of the 
p.Arg422* mutation and to determine whether this second mutation was located in cis or 
trans from the p.Arg239* germline mutation. No brain somatic mutation was identified in 
the second patient (individual 2/II-2). 
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DISCUSSION 
While DEPDC5 has been mainly linked to nonlesional familial focal epilepsies, particularly 
FFEVF, more recently mutations have also been detected in patients with focal epilepsy 
associated with cortical dysplasia and focal band heterotopia. 15 Thus, DEPDC5 mutations are 
associated with various focal epileptic phenotypes, across the spectrum from nonlesional 
familial focal epilepsies to malformation-associated focal epileptic syndromes (for review 1, 
26). Here, we confirm the existence of DEPDC5 mutations in patients with FCDs, and provide 
further information on the electroclinical, imaging and histological features, and on surgical 
outcome. Our findings have several original features: (1) the first report of patients with FCDs 
associated with DEPDC5 mutations who underwent epilepsy surgery, and demonstration of a 
favorable surgical outcome; (2) the presence of histologically confirmed FCD despite a 
normal MRI, raising the question of potential underestimation of FCDs in genetic focal 
epilepsies; (3) the association between FCD type IIa and DEPDC5 mutations suggesting that 
mTORC1 hyperactivation predicted in patients with mutations in DEPDC5 may also underlie 
different FCD subtypes, and not only type IIb; (4) the first report of a brain somatic mutation 
in DEPDC5 gene in one patient (out of two tested) in addition to an existing germline 
mutation supporting a two-hit hypothesis for FCD, and (5) a DEPDC5 germline mosaic 
mutation transmitted by an asymptomatic father.  
We previously reported that DEPDC5 mutations may be associated with a high rate of 
drug-resistance. 13 We now report in seven patients from four families the existence of FCD in 
the context of inherited drug-resistant focal epilepsies caused by DEPDC5 mutations. All 
patients had electroclinical phenotypes highly suggestive of FCD II. Epilepsy onset in infancy 
and early childhood (mean age: 18 months), high seizure frequency, drug-resistance and 
predominant location in fronto-central areas are characteristic of FCD II. 6, 28 In addition, 
sleep-related epilepsy previously reported as a clinical marker of FCD II 27 was observed in six 
out of seven patients. MRI showed typical features of FCD II in four patients and was 
considered normal in three others in accordance with the 30-40 % rate of MRI-negative FCD 
II cases observed in recent series. 28, 29 Of the three MRI negative cases, one had macroscopic 
abnormalities suggestive of FCD II and two had SEEG features typical of FCD II, concordant 
with focal hypometabolism on FDG-PET in one. This is concordant with a report showing that 
in patients with MRI-negative neocortical epilepsies, FDG-PET coregistered on MRI may help 
to detect occult FCD II. 30, 31 In our series, histological examination confirmed FCD II in two 
patients, yet failed to demonstrate FCD II in four operated/biopsied patients, which may be 
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due to technical reasons: fragmented specimens (individuals 1/IV-9, 1/V-1; 4/II-1), 
incomplete resection of the abnormal cortex (individuals 1/V-1, 4/II-1) and a biopsy 
(individual 3/IV-2), which was seemingly performed in the vicinity of the abnormal cortex. 
Finally, of the five patients who underwent resective surgery, three became seizure-free with 
a follow-up of 4 to 13 years and one had a worthwhile improvement, in accordance with the 
favorable surgical outcome usually obtained in FCD II, including MRI-negative cases. 6 In the 
two patients in whom surgery did not lead to seizure freedom, the location of the 
epileptogenic zone in functional areas precluded complete removal of the lesion.  
Despite a drug-resistance rate of ~ 30% in patients with familial focal epilepsies 24, 32, 
which may be higher when DEPDC5 is causal 13, epilepsy surgery is rarely performed. The 
reticence may derive from the absence of an MRI-detectable lesion and the presence of a 
mutated protein expressed ubiquitously throughout the cortex. Our study indicates that the 
presence of a DEPDC5 mutation in patients with refractory focal epilepsy (whether the brain 
MRI is normal or not) should not preclude epilepsy surgery, since it may cure the epilepsy. 
Therefore we believe that drug-resistant focal epilepsies should be evaluated for surgery 
even in the presence of a clear genetic etiology. A key question directly emanating from our 
findings is whether only a subset of family members develops FCD or whether infra-
radiological FCD is present in all affected family members. 
The finding that DEPDC5 is associated with FCD in the context of inherited focal epilepsy 
agrees with evidence that DEPDC5 acts as an mTORC1 inhibitor. 16 The role of DEPDC5 in the 
mTORC1 cascade is particularly attractive for two main reasons: 1/other genes encoding 
inhibitors of mTORC1 have been shown to cause brain malformations associated with 
refractory epilepsy 33, 34: inactivation of TSC1 or TSC2 causes tubers in TSC, deletion of 
STRADA causes PMSE syndrome, and loss-of-function of PTEN causes HME; 2/ enhanced 
constitutive mTORC1 activation has been shown in the balloon cells found in FCD IIb, which 
are thought to be the cellular marker traducing alterations of the pathway, but not in FCD IIa. 
35 Interestingly, we did not find FCD IIb cases in our families with DEPDC5 mutations, 
suggesting a continuum in both cellular and mTORC1 signaling alterations. 
A long-standing, yet unproven hypothesis, is that FCD is caused by brain somatic 
mutations, which are increasingly identified in neurodevelopmental diseases associated with 
epilepsy. 36 Also, in families comprising a patient with Dravet syndrome, a severe epileptic 
encephalopathy, 7 % of SCN1A mutations are inherited from a parent who is somatic or 
germline mosaic. 37 Interestingly, single cell sequencing of TSC1 and TSC2 in tubers revealed 
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both germline and somatic mutations reflecting a “two-hit” mutational event. 38 With the 
finding of DEPDC5 mutations in patients with cortical malformations, this hypothesis has 
become even more attractive. 26 We report a de novo somatic DEPDC5 mutation in the brain 
lesional specimen of one patient with FCD. This mutation, absent from blood DNA, and 
superimposed on an existing, different, heterozygous germline mutation, is likely to cause a 
biallelic inactivation of DEPDC5 at the site of the lesion, confirming a two-hit mutational 
model. However, we failed to detect a somatic mutation in a second patient, from another 
family. Sequencing and search for loss-of-heterozygosity of paired blood-brain DNA from 
additional patients will allow determination of the prevalence of DEPDC5 somatic mutations 
in FCDs, and may help to resolve the puzzling question of the variability of brain areas 
involved in different family members within families with FFEVF. Sequencing using gene 
panels has been shown to be a valuable technique to detect mosaic mutations in cerebral 
cortical malformations. 39  
To conclude, our study reveals that DEPDC5 mutations are associated with FCD in 
patients with familial focal epilepsy, who were originally considered as nonlesional. DEPDC5, 
like other mTORC1 inhibitor genes including TSC1, TSC2, PTEN or STRADA, may be 
responsible for structural alterations in the cortex with the presence of dysmorphic cells. 
Experimental studies on animal models are now needed to better understand the nature and 
extent of the consequent changes related to DEPDC5 mutations. In particular, it remains to 
be proven that constitutive mTORC1 activation contributes to DEPDC5-related epilepsy, as 
seen in other so-called mTORopathies. This would, of course, have important therapeutic 
implications.  
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FIGURE LEGENDS  
Figure 1: Pedigrees of the families with DEPDC5 mutation segregation. Pedigrees of family 1 
(p.Arg239*) and family 2 (c.484-1G >A) of French origin, family 3 (p.Arg422*) of American 
origin and family 4 (p.Arg587*) of French-Canadian origin are illustrated. Individuals with 
FCD are boxed (in red). The respective DEPDC5 mutations (NM_001242896.1, 
NP_001229825.1) are indicated. Individuals who carry a DEPDC5 mutation are denoted by 
m/+ and those negative for mutations are denoted by +/+. Level of mosaicism of c.484-1G 
>A mutation is indicated in brackets.  
Figure 2: MRI of patients 1/V-4 (A-D), 2/II-2(E) and 4/III-1 (F). (A, B), coronal slices, inverted 
T2 weighted sequences; (C, D) axial slices; C, T1 weighted; and D, FLAIR sequences. Typical 
features of FCD IIb located in the left mesial superior frontal gyrus (premotor area) with a 
broad gyrus, blurring of the grey-white matter demarcation, subcortical hypersignal and 
transmantle sign (arrows). (E), FDG-PET/MRI superimposition, coronal slice; note the focal 
hypometabolism in the anterior part of the left insula (arrow) corresponding to the seizure 
onset zone and the site of FCD IIa. (F), MRI of individual 4/III-1 showing a coronal view, 3D T1 
sequence. The white arrow shows the abnormal deep sulcus (FCD IIa) in the paramedian 
region of the right frontal pole. 
Figure 3: Hematoxylin and eosin stained paraffin-embedded tissue from post-operative brain 
sections in subject 2/II-2 (A-C) and 4/III-1 (B-D), showing the presence of large dysmorphic 
neurons (indicated by arrows) and cortical disorganization characteristic of FCD IIa. Scale bar 
= 50 µm, magnification A-B: X40, C-D: X20.  
Figure 4: Sequence chromatograms from patient 1/IV-9 showing the detection of p.Arg239* 
mutation in DEPDC5 exon 12 in blood and brain DNA, and p.Arg422* mutation in exon 18 in 
brain DNA. The mutation p.Arg422* was not detected from blood DNA indicating that it 
occurred de novo somatically.  
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